Company intelligence / Profile preview
Aptadir Therapeutics
Milan, Italyaptadir.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Aptadir is developing RNA inhibitor-based therapeutics that block aberrant DNA methylation at a single gene level, reactivating previously hypermethylated genes. Their lead candidate, Aptadir Ce-49 for MDS, has shown promising results in vitro and in vivo studies and is undergoing preliminary toxicity tests. The company aims to enter clinical trials by the end of 2025.
- Therapeutic areas
- OncologyRare DiseasesNeurologyHematology
- Modalities
- RNA therapeuticsRNA inhibitorsDiRs (DNMTs Interacting RNAs)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Aptadir Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aptadir Therapeutics.